FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2023

AFT Pharma reports growth and global expansion
Read More
FINANCIAL RESULTS FOR THE SIX MONTHS TO 30 SEPTEMBER 2023
Read More
AFT Pharmaceuticals announces the US FDA has approved Maxigesic IV®, the intravenous form of its patented pain relief medicine, for sale in the US, which represents AFT’s second FDA approval within one year.
Read More
AFT Pharmaceuticals announced today that it intends to release on Thursday November 23 2023 its half year interim results for the period ended September 30 2023.
Read More
AFT Pharmaceuticals today announces the appointment of Andrew Lane as an independent non-executive director.
Read More
Independent director Jon Lamb today retired from the board following his announcement at the ASM.
Read More
AFT Pharmaceuticals advises of the release yesterday evening by the High Court at Auckland of its judgment upholding in part claims by PBL Solutions Limited (PBL) against AFT, and dismissing others.
Read More
New Zealanders will find a home-grown answer to pain relief on the shelves at their local pharmacy this month with the launch of a new drug that represents a world breakthrough.
Read More